TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer

Li, Yaoqing; Xu, Chuchu; Zhu, Rui‐Liang; Shen, Liyijing; Hu, Gengyuan; Tao, Kelong; Tao, Feng; Lu, Zengxin; Zhang, Guolin

doi:10.1007/s00432-023-04670-w

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Li et al. identified elevated TIMP-2 expression in the serum of patients with CRC resistant to 5-fluorouracil (5-FU), a possible biomarker of 5-FU resistance ( 72 ). TIMP-3 preferentially inhibits MMP-2 and MMP-9.…”

Section: Matrix Metalloproteinasesmentioning

confidence: 99%

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

Sampaio Moura,

Schledwitz,

Alizadeh

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains a major cause of morbidity and mortality. Therapeutic approaches for advanced CRC are limited and rarely provide long-term benefit. Enzymes comprising the 24-member matrix metalloproteinase (MMP) family of zinc- and calcium-dependent endopeptidases are key players in extracellular matrix degradation, a requirement for colon tumor expansion, invasion, and metastasis; hence, MMPs are an important research focus. Compared to sporadic CRC, less is known regarding the molecular mechanisms and the role of MMPs in the development and progression of colitis-associated cancer (CAC) − CRC on a background of chronic inflammatory bowel disease (IBD) − primarily ulcerative colitis and Crohn’s disease. Hence, the potential of MMPs as biomarkers and therapeutic targets for CAC is uncertain. Our goal was to review data regarding the role of MMPs in the development and progression of CAC. We sought to identify promising prognostic and therapeutic opportunities and novel lines of investigation. A key observation is that since MMPs may be more active in early phases of CAC, using MMPs as biomarkers of advancing neoplasia and as potential therapeutic targets for adjuvant therapy in those with advanced stage primary CAC rather than overt metastases may yield more favorable outcomes.

show abstract

Section: Matrix Metalloproteinasesmentioning

confidence: 99%

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

Sampaio Moura,

Schledwitz,

Alizadeh

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, colorectal cancer is one of the most widespread cancers in developed nations, and studies have shown that different MMPs, including MT1‐MMP, play a role in both its onset and metastasis (Dibdiakova et al, 2022; Li et al, 2023; Pezeshkian et al, 2021; Zucker & Vacirca, 2004). However, the exact region in the intestinal mucosa involved in the initiation of this cancer remains to be reported.…”

Section: Introductionmentioning

confidence: 99%

MT1‐MMP and TIMP‐2 are first expressed in the colon glands after a single dose of azoxymethane (AOM)

da Silva,

Freitas,

do Carmo

et al. 2023

The Anatomical Record

View full text Add to dashboard Cite

Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) and membrane‐type 1‐matrix metalloproteinase (MT1‐MMP) are always expressed during the cancer process. The aim was to identify which regions of the colon mucosa MT1‐MMP and TIMP‐2 begin to express themselves, as well as to establish their expression in relation to cell proliferation and mucin production. After intraperitoneal injection of 15 mg/kg of azoxymethane (AOM) at 4, 12, and 20 weeks, histological sections of the middle segment of the rat colon mucosa were evaluated by immunohistochemistry for cell proliferation and expression of MT1‐MMP and TIMP‐2 and histochemistry for mucin. As a result, a single dose of AOM initially increased the intensity of MT1‐MMP and TIMP‐2 expression in the conjunctive cells and glands, concurrently with alterations in the distribution of the mucin produced in the gland of the large intestine mucosa and cell proliferation. As a result, at 4 and 12 weeks, a single dose of AOM initially stimulated the expression of MT1‐MMP and TIMP‐2 in the conjunctive cells and glands with greater intensity. Changes in the cell proliferation and distribution of the mucin produced in the large intestine mucosa gland were observed. We conclude that MT1‐MMP and TIMP‐2 were first and strongly expressed in all cells of the colon glands, concurrently with an increase in cell proliferation and a diffuse dispersion of mucin, indicating the onset of the dysplasia process following a single dosage of AOM.

show abstract

TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer

Cited by 2 publications

References 31 publications

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer

MT1‐MMP and TIMP‐2 are first expressed in the colon glands after a single dose of azoxymethane (AOM)

Contact Info

Product

Resources

About